Myosin-13 Activators

Blebbistatin, while primarily known to inhibit myosin II ATPase activity, would create a compensatory cellular demand for other myosin proteins, possibly including Myosin-13, to maintain essential cellular functions. ML-7 and Calyculin A target the phosphorylation balance within the cell. ML-7's inhibition of myosin light chain kinase could enhance the activity of Myosin-13 by reducing competition for actin binding sites, whereas Calyculin A's prevention of dephosphorylation via protein phosphatases PP1 and PP2A could result in an upsurge in Myosin-13 activity, again due to altered phosphorylation levels. Y-27632 and Wiskostatin modify the actomyosin contractility pathway and actin network formation, respectively, which in turn can lead to an increase in Myosin-13 activity as the cell attempts to stabilize its structural and motility functions.

Compounds like Jasplakinolide, Phalloidin, and Cytochalasin D, which act directly on the actin filaments, either by stabilizing or depolymerizing them, could necessitate an adaptive increase in Myosin-13 activity to counterbalance these effects and maintain cytoskeletal integrity. Forskolin, by activating adenylate cyclase and thus increasing cAMP levels, initiates a cascade that can enhance the action of Myosin-13, highlighting the interconnectedness of metabolic pathways and motor protein function. KN-93's inhibition of Ca2+/calmodulin-dependent protein kinase II might also result in elevated Myosin-13 activity as the cell's internal calcium signaling is perturbed.